Re: K191128
Trade/Device Name: Vantage Titan 3T, MRT-3010/A5, V2.50
Regulation Number: 21 CFR 892.1000
Regulation Name: Magnetic Resonance Diagnostic Device
Regulatory Class: Class II
Product Code: LNH
Dated: April 26, 2019
Received: April 29, 2019

June 26, 2019

Canon Medical Systems Corporation
Mr. Orlando Tadeo
Regulatory Affairs
Canon Medical Systems USA, Inc.
2441 Michelle Drive
TUSTIN CA 92780

Dear Mr. Tadeo:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for
devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.


For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

[Signature]
Thalia T. Mills, Ph.D.
Director
Division of Radiological Health
OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure
Indications for Use

Vantage Titan 3T systems are indicated for use as a diagnostic imaging modality that produces cross-sectional transaxial, coronal, sagittal, and oblique images that display anatomic structures of the head or body. Additionally, this system is capable of non-contrast enhanced imaging, such as MRA.

MRI (magnetic resonance imaging) images correspond to the spatial distribution of protons (hydrogen nuclei) that exhibit nuclear magnetic resonance (NMR). The NMR properties of body tissues and fluids are:

- Proton density (PD) (also called hydrogen density)
- Spin-lattice relaxation time (T1)
- Spin-spin relaxation time (T2)
- Flow dynamics
- Chemical Shift

Depending on the region of interest, contrast agents may be used. When interpreted by a trained physician, these images yield information that can be useful in diagnosis.
510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of Safe Medical Device Act 1990 and 21 CFR § 807.92

1. CLASSIFICATION and DEVICE NAME

<table>
<thead>
<tr>
<th>Classification Name:</th>
<th>Magnetic Resonance Diagnostic Device</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regulation Number:</td>
<td>90-LNH (Per 21 CFR § 892.1000)</td>
</tr>
<tr>
<td>Trade Proprietary Name:</td>
<td>Vantage Titan 3T</td>
</tr>
<tr>
<td>Model Number:</td>
<td>MRT-3010/A5, V2.50</td>
</tr>
</tbody>
</table>

2. SUBMITTER’S NAME

Canon Medical Systems Corporation
1385 Shimoishigami
Otawara-Shi, Tochigi-ken, Japan 324-8550

3. OFFICIAL CORRESPONDENT

Naofumi Watanabe
Senior Manager, Regulatory Affairs and Vigilance
Canon Medical Systems Corporation

4. CONTACT PERSON, U.S. AGENT and ADDRESS

Contact Person
Janine F. Reyes
Manager, Regulatory Affairs
Canon Medical Systems USA, Inc.
2441 Michelle Drive, Tustin, CA 92780
Phone: (714) 669-7853
Fax: (714) 730-1310
E-mail: jreyes@us.medical.canon

Official Correspondent/U.S. Agent
Paul Biggins
Senior Director, Regulatory Affairs
Canon Medical Systems USA, Inc.
2441 Michelle Drive, Tustin, CA 92780
Phone: (714) 730-7808
Fax: (714) 730-1310
E-mail: pbiggins@us.medical.canon
5. MANUFACTURING SITE
Canon Medical Systems Corporation
1385 Shimoishigami
Otawara-shi, Tochigi 324-8550, Japan

6. ESTABLISHMENT REGISTRATION
9614698

7. DATE PREPARED
April 26, 2019

8. DEVICE NAME
Vantage Titan 3T, MRT-3010/A5, V2.50

9. TRADE NAME
Vantage Titan 3T, MRT-3010/A5, V2.50

10. CLASSIFICATION NAME
Magnetic Resonance Diagnostic Device (MRDD)

11. CLASSIFICATION PANEL
Radiology

12. DEVICE CLASSIFICATION
Class II (per 21 CFR 892.1000, Magnetic Resonance Diagnostic Device)

13. PRODUCT CODE
90-LNH

14. PREDICATE DEVICE
Predicate Device (system): Vantage Titan 3T, MRT-3010/A5, V2.50

<table>
<thead>
<tr>
<th>System</th>
<th>Subject</th>
<th>Predicate Device</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vantage Titan 3T, MRT-3010/A5, V2.50</td>
<td>Vantage Titan 3T, MRT-3010/A5, V2.50</td>
<td></td>
</tr>
<tr>
<td>Marked By</td>
<td>Canon Medical Systems USA, Inc.</td>
<td>Canon Medical Systems USA, Inc.</td>
</tr>
<tr>
<td>510(k) Number</td>
<td>This Submission</td>
<td>K143008</td>
</tr>
<tr>
<td>Clearance Date</td>
<td></td>
<td>April 9th, 2015</td>
</tr>
</tbody>
</table>

15. REASON FOR SUBMISSION
Modification of a cleared device

16. SUBMISSION TYPE
Traditional 510(k) Premarket Notification
17. DEVICE DESCRIPTION
The Vantage Titan 3T (Model MRT-3010/A5) is a 3 Tesla Magnetic Resonance Imaging (MRI) System, previously cleared under K143008. This system is based upon the technology and materials of previously marketed Canon Medical Systems MRI systems and is intended to acquire and display cross-sectional transaxial, coronal, sagittal, and oblique images of anatomic structures of the head or body.

18. SUMMARY OF CHANGE(S)
This submission is to report the following software functionalities have been added:

- mART: Metal Artifact Reduction Technique
- mART+: Metal Artifact Reduction Technique with the addition of View Angle Tilting (VAT)

19. SAFETY PARAMETERS

<table>
<thead>
<tr>
<th>Item</th>
<th>Subject Device: Vantage Titan 3T, MRT-3010/A5, V2.50</th>
<th>Predicate Device: Vantage Titan 3T, MRT-3010/A5, V2.50</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Static field strength</td>
<td>3T</td>
<td>3T</td>
<td>Same</td>
</tr>
<tr>
<td>Operational Modes</td>
<td>Normal and 1st Operating Mode</td>
<td>Normal and 1st Operating Mode</td>
<td>Same</td>
</tr>
<tr>
<td>i. Safety parameter display</td>
<td>SAR, dB/dt</td>
<td>SAR, dB/dt</td>
<td>Same</td>
</tr>
<tr>
<td>ii. Operating mode access requirements</td>
<td>Allows screen access to 1st level operating mode</td>
<td>Allows screen access to 1st level operating mode</td>
<td>Same</td>
</tr>
<tr>
<td>Potential emergency condition and means provided for shutdown</td>
<td>Shutdown by Emergency Ramp Down Unit for collision hazard for ferromagnetic objects</td>
<td>Shutdown by Emergency Ramp Down Unit for collision hazard for ferromagnetic objects</td>
<td>Same</td>
</tr>
</tbody>
</table>

20. IMAGING PERFORMANCE PARAMETERS
No change from the previous predicate submission, K143008.

21. INDICATIONS FOR USE
Vantage Titan 3T systems are indicated for use as a diagnostic imaging modality that produces cross-sectional transaxial, coronal, sagittal, and oblique images that display anatomic structures of the head or body. Additionally, this system is capable of non-contrast enhanced imaging, such as MRA.
MRI (magnetic resonance imaging) images correspond to the spatial distribution of protons (hydrogen nuclei) that exhibit nuclear magnetic resonance (NMR). The NMR properties of body tissues and fluids are:

- Proton density (PD) (also called hydrogen density)
- Spin-lattice relaxation time (T1)
- Spin-spin relaxation time (T2)
- Flow dynamics
- Chemical Shift

Depending on the region of interest, contrast agents may be used. When interpreted by a trained physician, these images yield information that can be useful in diagnosis.

22. SUMMARY OF DESIGN CONTROL ACTIVITIES

Design controls for the software functionalities were conducted under K143008. The functionalities in this submission are embedded in software version 2.5. There are no new design control activities to report as part of this device modification.

23. SAFETY

This device is designed and manufactured under the Quality System Regulations as outlined in 21 CFR § 820 and ISO 13485 Standards.

This device is based upon the same technologies, materials and software as the predicate device. Risk activities were conducted in concurrence with established medical device development standards and guidance. Additionally, testing was done in accordance with applicable recognized consensus standards published by the International Electrotechnical Commission (IEC) for medical devices and the National Electrical Manufacturers Association (NEMA):

LIST OF APPLICABLE STANDARDS

- IEC60825-1 (2007)
- IEC62304 (2006)
- NEMA MS 1 (2008)
- NEMA MS 2 (2008)
- NEMA MS 3 (2008)
- NEMA MS 4 (2010)
- NEMA MS 5 (2010)

24. TESTING

Software Documentation for a Moderate Level of Concern, per the FDA guidance document, “Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices Document” issued on May 11, 2005, was included in K143008.
Bench testing utilizing both phantom and representative clinical images were obtained to demonstrate the subject device is capable of reducing metal related artifacts on MR images.

25. SUBSTANTIAL EQUIVALENCE
Canon Medical Systems Corporation believes that the Vantage Titan 3T, MRT-3010/A5, V2.50 Magnetic Resonance Imaging (MRI) System is substantially equivalent to the previously cleared predicate device, Vantage Titan 3T, MRT-3010/A5, V2.50, referenced in this submission. Canon Medical Systems Corporation believes that the changes incorporated into the Vantage Titan 3T, MRT-3010/A5, V2.50 are substantially equivalent to the previously cleared predicate device.

26. CONCLUSION
The implementation of mART and mART+ on the Vantage Titan 3T, MRT-3010/A5, V2.5 software do not change the indications for use or the intended use of the device. Based upon bench testing, phantom imaging, volunteer clinical imaging, successful completion of software validation and application of risk management and design controls, it is concluded that the subject device is safe and effective for its intended use.